Aspire Biopharma Holdings, Inc. 8-KCurrent Reports (8-K / ad hoc)

Financial Statements

Item 8.01 Other Events Pursuant to requests from holders of the Company’s public warrants (the “Public Warrants”), Aspire Biopharma Holdings, Inc. (the “Company”) wanted to clarify the terms of the Company’s public warrants which trade under the symbol “ASPBW”. The Warrants were originally issued on February 23, 2022 in connection with the initial public offering of Power Up Acquisition Corp. which was the Company’s predecessor. The Warrants had an initial exercise price which was $11.50 per share subject to adjustment in certain events including a consolidation of the Company’s outstanding shares. On January 16, 2026, the Company affected a reverse stock split of 1 for 30 and on May 11, 2026, the Company effected an additional reverse split of its common stock in a ratio of 40-1. As a result of the two reverse splits, the Warrants now have an exercise price of $13,800 per share and a ratio of 1,200 Warrants to purchase one share of common stock. Field: Page; Sequence: 2 Field: /Page SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 20, 2026 Aspire Biopharma Holdings, Inc. By: /s/ Kraig T. Higginson Name: Kraig T. Higginson Title: Chief Executive Officer and Chairman Field: Page; Sequence: 3; Options: Last Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kdFqwjAUhp/AdziUXYqmgSn0bitVxnQWFbfbWE9nsM0pJ9HpI+0tl6YTvdhCICTn/N//HxJF/WhKE10hw8fzcgZrrJtKOYQllshoCvQd6ctrAv5c4qe2jpVx4XoVpuQ16DWjwaPy76HzpC3uEhDjoRRDOYJYJnIM+TzqtfWUTKl3aJxWFSizg5ypYY1O8aUjrNWZDNWX4LRBtppMAvFAdOVvkCKW8EYn9UV8sDCbpVGvH1YvmjIdG9+VnR2aVglZhbW3s536tkOa4mgd1cm74nY2m6lin52RC23VtsIJ8cLgaq8YF6WftSazclQc5lhvkb08FlLG4uk32ZXSB/QcwBsISmIgg2BbFlAJRaCBbXF/BLozyxVvVHVEMRBCxDlyyPNPhPQO24dGMZxaLTx0amj8p4UMV88fwIOeQw==